C
Candel Therapeutics
Developing oncolytic viral immunotherapies that light up and empower the immune system to fight cancer
About Candel Therapeutics
Candel Therapeutics is at the forefront of developing innovative viral immunotherapies aimed at educating the immune system to recognize and eliminate tumor cells. The company operates in the oncology sector, focusing on creating treatments that combine anti-tumor and immune-stimulatory components. These therapies are designed to cause in situ vaccination against unique antigens and neoantigens presented when tumor cells lyse, thereby activating both innate and adaptive immune mechanisms. Candel Therapeutics primarily serves patients with various forms of cancer, including those with non-small cell lung cancer (NSCLC) who have shown suboptimal responses to first-line anti-PD-L1 inhibitor therapy. The company is currently enrolling patients in multiple U.S. centers for a Phase 2 clinical trial. The business model revolves around the development and clinical testing of these transformative immunotherapies, with revenue generated through partnerships, clinical trial enrollments, and eventual commercialization of successful treatments. Candel Therapeutics aims to improve lives by fostering a collaborative and innovative environment, encouraging creativity and efficiency among its teams.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1999
- Headquarters
- Needham, United States
- Listing
- IPO 2021
- Employees
- 87
- Open positions
- 13
- Dealroom signal
- 90.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBTDebt | Oct 2025 | $130M | — | Trinity Capital | ↗ |
| POST IPO EQUITYOther financing | Jun 2025 | $15M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$43M | — |
| 2025 | $0 | — | −$43M | — |
| 2024 | $0 | — | −$31M | — |
| 2023 | $0 | -100% | −$35M | — |
| 2022 | $125K | 0% | −$51M | -40835.2% |
| 2021 | $125K | 0% | −$24M | -19534.4% |
| 2020 | $125K | — | −$8.5M | -6792% |
Growth signals
Latest recorded traffic for Candel Therapeutics is 9.2K monthly website visits, up 17.9% over the last three months. Candel Therapeutics's team grew 17.6% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Massachusetts Life Sciences Center
US Department of Health and Human Services
Series A2 investors entered at this stage
National Securities Corporation- PGPBM Capital Group
Series B and later3 investors entered at this stage
Standard Treasury
Silicon Valley Bank
Trinity Capital
Other known investors1 additional known investor
Harvard Medical School
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Candel Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Candel Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.